Cancer Chemotherapy and vitamin D – Review March 2013

Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs Used in Cancer Patients: A Systematic Review

Cancers 2013, 5(1), 255-280; doi:10.3390/cancers5010255
Deborah A. Kennedy 1 , Kieran Cooley 1 , Becky Skidmore 1 Heidi Fritz 1 , Tara Campbell 1 email and Dugald Seely 1,2, dseely@ccnm.edu
1 Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario, M2K 1E2, Canada 2 Ottawa Integrative Cancer Centre, 29 Bayswater Avenue, Ottawa, Ontario, K1Y 2E5, Canada

Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol.

The half-life of 25(OH)D3 and/or 1,25(OH)2D3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs.

No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH)2D3 supplementation, were revealed through this review.

While sufficient evidence is lacking, supplementation with 1,25(OH)2D3 during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D3 have not been studied.



Image Image


PDF is attached at the bottom of this page

See also VitaminDWiki

see wikipage: http://www.vitamindwiki.com/tiki-index.php?page_id=396

9702 visitors, last modified 29 Jun, 2018,
Printer Friendly Follow this page for updates